Investing.com - Ultragenyx (NASDAQ: RARE) reported third quarter EPS of $-1.40, $0.08 better than the analyst estimate of $-1.48. Revenue for the quarter came in at $139.45M versus the consensus estimate of $135.28M.
Guidance
Ultragenyx sees FY 2024 revenue of $530.00M-$550.00M versus the analyst consensus of $537.00M.
Ultragenyx's stock price closed at $52.18. It is up 4.30% in the last 3 months and up 38.08% in the last 12 months.
Ultragenyx saw 8 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Ultragenyx's stock price’s past reactions to earnings here.
According to InvestingPro, Ultragenyx's Financial Health score is "fair performance".
Check out Ultragenyx's recent earnings performance, and Ultragenyx's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar